Skip to main content
Clinical Trials/NCT04146142
NCT04146142
Completed
Not Applicable

A Prospective Randomized Trial of Antibiotic Prophylaxis Versus None Before Transperineal MRI-TRUS Fusion Guided Prostate Biopsy

Oslo University Hospital2 sites in 2 countries550 target enrollmentNovember 11, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Biopsy
Sponsor
Oslo University Hospital
Enrollment
550
Locations
2
Primary Endpoint
Incidence of sepsis
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Prostate biopsy is indicated in patients with suspected prostate cancer and has been traditionally performed through the rectum using antibiotic prophylaxis. Increasing antibiotic resistance of intestinal bacteria is causing a growing number of patients to get post-biopsy infections. Sepsis rate after transrectal biopsies is approximately 4-10%.

To reduce the risk of post-biopsy infections, transperineal approach in general anesthesia and antibiotic prophylaxis has been used. The investigators at Oslo University Hospital Aker developed MRI -TURS elastic image fusion guided transperineal prostate biopsy technique in local anesthesia and Bactrim prophylaxis as outpatient procedure. The investigators found 0.4% post-biopsy infection rate. Afterwards a pilot study using the same biopsy technique however without antibiotic prophylaxis was realized in 90 patients. None of these subjects experienced infection.

The investigators wish to perform a prospective randomized trial of antibiotic prophylaxis versus none before transperineal MRI-TRUS fusion guided prostate biopsy in local anesthesia in outpatient clinic.

Detailed Description

Background: Unnecessary use of antibiotics promotes antibiotic resistance. Efforts for antibiotic use reduction without increase the risk of serious infection complications are therefore needed. Purpose: The aim of this trial is to compare the rates of infectious complication after transperineal prostate biopsy in patients with and without antibiotic prophylaxis. Materials and methods: A total of 450 patients will be included in this trial. A 1:1 randomization to receive or not receive antibiotics prophylaxis will be performed using randomization system WebCRF-3 system. MRI-TRUS fusion prostate biopsy will be done with transperineal prostate approach in local anesthesia in outpatient clinic. In patients with normal MRI,12-core systematic prostate biopsies with 3D biopsy registration will be done according to the EAU guidelines. In patients with positive MRI, 2-4 targeted biopsies from the suspicious MRI areas will be realized and systematic prostate biopsies will also be done. All prostate biopsies will be performed using Koelis MRI-TRUS image fusion and organ based tracking system. Post-biopsy infection and any adverse events will be systematically prospectively registered in all patients. Pain during the local anesthesia application and during the biopsy procedure will be registered using Visual Analog Score, 10 points scale questionnaire.

Registry
clinicaltrials.gov
Start Date
November 11, 2019
End Date
April 30, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Sponsor
Oslo University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Eduard Baco

Principal investigator

Oslo University Hospital

Eligibility Criteria

Inclusion Criteria

  • Clinical indication for prostate cancer

Exclusion Criteria

  • Patients with symptoms of urinary tract infection or positive findings on urine dipstic before biopsy
  • Patients with indwelling urethral catheter
  • Patients with immunodeficiency disorders
  • Patients with high risk for infective endocarditis \[European Society of Cardiology\]
  • Patients with a prosthetic aortic or pulmonary valve
  • Patients with previous infective endocarditis
  • Patients with congenital heart disease who are cyanotic and those who have had palliative shunts/conduits/other prostheses
  • Patients with a history of thromboembolic disease
  • Patients with a history of allergy to the study drug
  • Patients who do not wish to participate in the study

Outcomes

Primary Outcomes

Incidence of sepsis

Time Frame: Up to 30 days

Post biopsy sepsis will be defined by SIRS criteria

Incidence of post biopsy urinary tract infection

Time Frame: Up to 30 days

Post biopsy urinary tract infection not demanding hospital admission within 30

Study Sites (2)

Loading locations...

Similar Trials